4/18
01:00 am
lgvn
Low
Report
4/10
09:55 am
lgvn
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Low
Report
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
4/8
09:15 am
lgvn
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Medium
Report
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
3/18
10:00 am
lgvn
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
Medium
Report
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
3/18
09:44 am
lgvn
Longeveron (LGVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Longeveron (LGVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/17
07:26 pm
lgvn
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/17
04:05 pm
lgvn
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Low
Report
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
3/16
09:39 am
lgvn
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results [Yahoo! Finance]
High
Report
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results [Yahoo! Finance]
3/12
05:07 pm
lgvn
A $30 Million Reason to Buy Penny Stock Longeveron Today [Yahoo! Finance]
High
Report
A $30 Million Reason to Buy Penny Stock Longeveron Today [Yahoo! Finance]
3/12
09:00 am
lgvn
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Low
Report
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
3/11
04:05 pm
lgvn
Longeveron Announces Closing of Private Placement of up to $30 Million
Low
Report
Longeveron Announces Closing of Private Placement of up to $30 Million
3/10
09:00 am
lgvn
Longeveron Announces Private Placement of up to $30 Million
High
Report
Longeveron Announces Private Placement of up to $30 Million
2/25
11:26 am
lgvn
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]
Medium
Report
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]
2/25
11:05 am
lgvn
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Medium
Report
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
2/13
04:41 pm
lgvn
Longeveron appoints new CEO [Seeking Alpha]
Low
Report
Longeveron appoints new CEO [Seeking Alpha]
2/13
04:30 pm
lgvn
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Low
Report
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
2/5
09:15 am
lgvn
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Medium
Report
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
1/29
09:15 am
lgvn
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Medium
Report
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
1/26
09:23 am
lgvn
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) [Yahoo! Finance]
Medium
Report
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) [Yahoo! Finance]
1/26
09:15 am
lgvn
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Medium
Report
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)